Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Biogen acquired an IND-ready asset from Karyopharm Therapeutics for $10 million upfront.

The FDA approved Mitsubishi Tanabe Pharma’s treatment for the fatal neurological disorder amyotrophic lateral sclerosis (ALS), the first such U.S. regulatory approval in more than two decades.